Medical device maker

Cygnus

(CYGN)

said it has launched its noninvasive glucose monitoring system in the U.S.

The watchlike device known as the GlucoWatch Biographer is a prescription product that attaches to the forearm and takes glucose readings through the skin. Currently, it is the only product approved by the Food and Drug Administration for noninvasive glucose monitoring.

The company plans to offer the product through mail order instead of at pharmaceutical retail stores.

Shares of Cygnus were recently up 14.1% to $6.61 on the news after closing at $5.79 on Friday.